炎症性肠病父系用药与男性生育力及生殖结局:系统综述与荟萃分析
该系统综述与荟萃分析检索了截至2022年4月的文献,纳入10项精液参数研究(268例炎症性肠病男性患者)和16项不良妊娠结局研究(超过25000例炎症性肠病男性患者),评估生物制剂、硫嘌呤或甲氨蝶呤暴露与精液参数及不良妊娠结局的关联。结果显示,暴露与精子数量、活力或形态异常无显著关联,父系暴露的不良妊娠结局患病率与未暴露者相当,生物制剂、硫嘌呤或甲氨蝶呤使用与不良妊娠结局风险无显著关联。
要点
- 生物制剂、硫嘌呤或甲氨蝶呤暴露与精子数量、活力或形态异常无显著关联。
- 父系生物制剂暴露不良妊娠结局患病率为5%,与未暴露者5%相当。
- 生物制剂、硫嘌呤或甲氨蝶呤使用与早期妊娠丢失、早产或先天畸形风险无显著关联。
核心结论
- 男性炎症性肠病患者使用生物制剂、硫嘌呤或甲氨蝶呤与生育力受损或不良妊娠结局风险增加无显著关联。
研究设计与样本
- 系统综述与荟萃分析,检索Medline、Embase、Scopus和Web of Science(PROSPERO CRD42020197098)自建库至2022年4月。
- 纳入10项报告精液参数的研究(268例炎症性肠病患者)和16项报告不良妊娠结局的研究(超过25000例炎症性肠病患者)。
- 采用随机效应模型汇总标准化均数差、患病率和比值比(OR)。
主要发现
- 与未暴露患者相比,生物制剂、硫嘌呤或甲氨蝶呤使用与精子数量、活力或形态异常减少无显著关联。
- 父系生物制剂暴露的不良妊娠结局患病率为5%,硫嘌呤暴露为6%,甲氨蝶呤暴露为6%,未暴露者为5%。
- 生物制剂使用与早期妊娠丢失风险无显著关联(OR 1.26;I²=0%;P=0.12)。
- 生物制剂使用与早产风险无显著关联(OR 1.10;I²=0%;P=0.17),与先天畸形风险无显著关联(OR 1.03;I²=0%;P=0.69)。
- 硫嘌呤使用与早期妊娠丢失风险无显著关联(OR 1.31;I²=19%;P=0.17),与早产风险无显著关联(OR 1.05;I²=0%;P=0.20),与先天畸形风险无显著关联(OR 1.07;I²=7%;P=0.34)。
关键数值与推荐
- 生物制剂使用与早期妊娠丢失风险无显著关联(OR 1.26;I²=0%;P=0.12)。
- 硫嘌呤使用与早期妊娠丢失风险无显著关联(OR 1.31;I²=19%;P=0.17)。
- 甲氨蝶呤使用与早产风险无显著关联(OR 1.06;I²=0%;P=0.62)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Studies evaluating reproductive outcomes among male patients with inflammatory bowel disease (IBD) are limited. We evaluated use of IBD medications and association with semen parameters, a proxy of male fertility, and adverse pregnancy outcomes (early pregnancy loss [EPL], preterm birth [PB], congenital malformations [CM]). METHODS: We searched Medline, Embase, Scopus, and Web of Science (PROSPERO CRD42020197098) from inception to April 2022 for studies reporting semen parameters and adverse pregnancy outcomes among male patients exposed to biologics, thiopurine, or methotrexate. Standardized mean difference, prevalence, and odds ratios (ORs) of outcomes were pooled and analyzed using a random effects model. RESULTS: Ten studies reporting semen parameters (268 patients with IBD) and 16 studies reporting adverse pregnancy outcomes (over 25,000 patients with IBD) were included. Biologic, thiopurine, or methotrexate use were not associated with decreased sperm count, motility, or abnormal morphology compared with nonexposed patients. The prevalence of adverse pregnancy outcomes with paternal biologic (5%), thiopurine (6%), or methotrexate (6%) exposure was comparable to nonexposed patients (5%). Biologic use was not associated with risk of EPL (OR, 1.26; I2 = 0%; P = .12), PB (OR, 1.10; I2 = 0%; P = .17), or CM (OR, 1.03; I2 = 0%; P = .69). Thiopurine use was not associated with risk of EPL (OR, 1.31; I2 = 19%; P = .17), PB (OR, 1.05; I2 = 0%; P = .20), or CM (OR, 1.07; I2 = 7%; P = .34). Methotrexate use was not associated with risk of PB (OR, 1.06; I2 = 0%; P = .62) or CM (OR, 1.03; I2 = 0%; P = .81). CONCLUSIONS: Biologic, thiopurine, or methotrexate use among male patients with IBD are not associated with impairments in fertility or with increased odds of adverse pregnancy outcomes.
引用
- Gubatan J, Barber GE, Nielsen OH, et al. Paternal Medications in Inflammatory Bowel Disease and Male Fertility and Reproductive Outcomes: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022. PMID: 35870769. doi:10.1016/j.cgh.2022.07.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。